-
Something wrong with this record ?
Signalling pathways in a nutshell: from pathogenesis to therapeutical implications in prostate cancer
AP. Goncharov, C. Dicusari Elissaiou, E. Ben Aharon Farzalla, G. Akhvlediani, N. Vashakidze, G. Kharaishvili
Language English Country England, Great Britain
Document type Journal Article, Review
NLK
Directory of Open Access Journals
from 2021
PubMed Central
from 2019
Taylor & Francis Open Access
from 2021-01-01
Medline Complete (EBSCOhost)
from 2002-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2002
- MeSH
- Epithelial-Mesenchymal Transition physiology MeSH
- Humans MeSH
- Prostatic Neoplasms * pathology metabolism therapy drug therapy MeSH
- NF-kappa B metabolism MeSH
- Hedgehog Proteins metabolism MeSH
- Signal Transduction * physiology MeSH
- Transforming Growth Factor beta metabolism MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
From tumorigenesis to the establishment of local or metastatic high-grade tumours, an integral part of the cellular lifespan relies on various signalling pathways. Particular pathways that allow cells to proliferate by creating a network of new blood vessels have been documented, whereas other pathways are primarily involved with a migration to distant body parts, partially through the process of epithelial-mesenchymal transition (EMT). This review will discuss the different signalling pathways, such as TGF-β, Cripto-1, Wnt pathways, Hedgehog, Notch and NF-κB pathways, and how they promote tumour initiation and progression by influencing diverse cellular processes and EMT in general and in benign and malignant prostate tumours. This review will discuss only the critical pathways. Therefore, many other types of signalling pathways which are related to prostate cancer will not be discussed. Possibilities for further investigation will be mentioned, as many underlying mechanisms involved in these pathways have potential as targets in future tumour therapy. This review will also introduce some novel clinical trials relating to the inhibition of signalling pathways and their clinical outcomes.
American Hospital in Tbilisi Tbilisi Georgia
Department of Clinical and Molecular Pathology Palacky University Olomouc Czech Republic
Department of Clinical and Molecular Pathology University Hospital Olomouc Czech Republic
Department of Oncology University Hospital Olomouc Czech Republic
Faculty of Medicine Georgian American University Tbilisi Georgia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015080
- 003
- CZ-PrNML
- 005
- 20250731090742.0
- 007
- ta
- 008
- 250708s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/07853890.2025.2474175 $2 doi
- 035 __
- $a (PubMed)40372974
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Goncharov, Aviv Philip $u Department of Clinical and Molecular Pathology, Palacky University, Olomouc, Czech Republic $u Department of Oncology, University Hospital, Olomouc, Czech Republic $1 https://orcid.org/0009000118113535
- 245 10
- $a Signalling pathways in a nutshell: from pathogenesis to therapeutical implications in prostate cancer / $c AP. Goncharov, C. Dicusari Elissaiou, E. Ben Aharon Farzalla, G. Akhvlediani, N. Vashakidze, G. Kharaishvili
- 520 9_
- $a From tumorigenesis to the establishment of local or metastatic high-grade tumours, an integral part of the cellular lifespan relies on various signalling pathways. Particular pathways that allow cells to proliferate by creating a network of new blood vessels have been documented, whereas other pathways are primarily involved with a migration to distant body parts, partially through the process of epithelial-mesenchymal transition (EMT). This review will discuss the different signalling pathways, such as TGF-β, Cripto-1, Wnt pathways, Hedgehog, Notch and NF-κB pathways, and how they promote tumour initiation and progression by influencing diverse cellular processes and EMT in general and in benign and malignant prostate tumours. This review will discuss only the critical pathways. Therefore, many other types of signalling pathways which are related to prostate cancer will not be discussed. Possibilities for further investigation will be mentioned, as many underlying mechanisms involved in these pathways have potential as targets in future tumour therapy. This review will also introduce some novel clinical trials relating to the inhibition of signalling pathways and their clinical outcomes.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory prostaty $x patologie $x metabolismus $x terapie $x farmakoterapie $7 D011471
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a signální transdukce $x fyziologie $7 D015398
- 650 _2
- $a epitelo-mezenchymální tranzice $x fyziologie $7 D058750
- 650 _2
- $a transformující růstový faktor beta $x metabolismus $7 D016212
- 650 _2
- $a proteiny hedgehog $x metabolismus $7 D053823
- 650 _2
- $a NF-kappa B $x metabolismus $7 D016328
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Dicusari Elissaiou, Constantinos $u Department of Clinical and Molecular Pathology, Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Ben Aharon Farzalla, Elad $u Department of Clinical and Molecular Pathology, Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Akhvlediani, Giorgi $u Faculty of Medicine, Georgian-American University, Tbilisi, Georgia $u American Hospital in Tbilisi, Tbilisi, Georgia $u Faculty of Medicine, University of Georgia, Tbilisi, Georgia
- 700 1_
- $a Vashakidze, Nino $u Department of Clinical and Molecular Pathology, Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Kharaishvili, Gvantsa $u Department of Human Morphology and Pathology, Medical Faculty, David Tvildiani Medical University, Tbilisi, Georgia $u Department of Clinical and Molecular Pathology, University Hospital, Olomouc, Czech Republic $1 https://orcid.org/0000000336186145
- 773 0_
- $w MED00009195 $t Annals of medicine $x 1365-2060 $g Roč. 57, č. 1 (2025), s. 2474175
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40372974 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731090736 $b ABA008
- 999 __
- $a ok $b bmc $g 2366146 $s 1252205
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 57 $c 1 $d 2474175 $e 20250515 $i 1365-2060 $m Annals of medicine $n Ann Med $x MED00009195
- LZP __
- $a Pubmed-20250708